CORSO, Simona
 Distribuzione geografica
Continente #
NA - Nord America 3.383
EU - Europa 1.652
AS - Asia 1.241
SA - Sud America 32
OC - Oceania 22
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.344
Nazione #
US - Stati Uniti d'America 3.349
CN - Cina 639
IT - Italia 572
SG - Singapore 290
IE - Irlanda 185
DE - Germania 168
SE - Svezia 164
FR - Francia 130
FI - Finlandia 89
UA - Ucraina 85
GB - Regno Unito 70
KR - Corea 70
JP - Giappone 56
PL - Polonia 53
VN - Vietnam 45
NL - Olanda 39
IN - India 35
ID - Indonesia 32
CA - Canada 24
BE - Belgio 21
AU - Australia 17
HK - Hong Kong 17
AT - Austria 15
IR - Iran 13
BR - Brasile 12
TW - Taiwan 12
ES - Italia 11
PT - Portogallo 9
RU - Federazione Russa 9
TR - Turchia 8
CL - Cile 7
GR - Grecia 7
IL - Israele 7
CH - Svizzera 6
KE - Kenya 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
AR - Argentina 4
DK - Danimarca 4
GT - Guatemala 4
MX - Messico 4
PE - Perù 4
LK - Sri Lanka 3
RO - Romania 3
SN - Senegal 3
TH - Thailandia 3
CO - Colombia 2
EU - Europa 2
HU - Ungheria 2
MY - Malesia 2
SI - Slovenia 2
AM - Armenia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EG - Egitto 1
GH - Ghana 1
IM - Isola di Man 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MM - Myanmar 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
TN - Tunisia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 6.344
Città #
Chandler 327
Ann Arbor 313
Houston 267
Fairfield 266
Santa Clara 226
Singapore 216
Beijing 207
Dublin 185
Woodbridge 140
Ashburn 107
Wilmington 104
Seattle 100
Cambridge 99
Torino 85
Nyköping 74
Dearborn 67
Turin 63
Villeurbanne 63
Jacksonville 53
Medford 53
Princeton 52
Columbus 50
Nanjing 50
Pisa 50
Warsaw 47
Milan 46
Shanghai 40
Guangzhou 36
Jakarta 32
Dong Ket 28
New York 28
Hangzhou 27
Redwood City 27
Boston 25
Groningen 22
San Diego 21
Los Angeles 18
Brussels 17
Helsinki 16
Vienna 15
Boardman 14
Fremont 14
Rome 14
Jinan 13
Munich 13
Tokyo 13
Florence 12
Zhengzhou 12
Carrara 11
London 11
Changsha 9
Chengdu 9
Hefei 9
Mumbai 9
Seoul 9
Genoa 8
Kunming 8
Verona 8
Wuhan 8
Amsterdam 7
Hebei 7
Hong Kong 7
Nanchang 7
Norwalk 7
Ottawa 7
Paris 7
San Jose 7
Taipei 7
Upper Marlboro 7
Falls Church 6
Fukushima 6
San Antonio 6
Silver Spring 6
Washington 6
Barcelona 5
Gainesville 5
Lappeenranta 5
Moncalieri 5
Nantong 5
Salerno 5
San Mateo 5
Varese 5
Chongqing 4
Delhi 4
Duncan 4
Eitensheim 4
Lima 4
Norwich 4
Nürnberg 4
Phoenix 4
Porcia 4
Qingdao 4
Rajkot 4
Reston 4
Shenyang 4
São Paulo 4
Tampa 4
Temuco 4
Tianjin 4
Trento 4
Totale 4.078
Nome #
How Can Gastric Cancer Molecular Profiling Guide Future Therapies? 396
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts 294
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 282
Personalized therapeutic strategies in HER2-driven gastric cancer 261
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 260
Enhanced c-Met activity promotes G-CSF induced mobilization of hematopoietic progenitor cells via ROS signaling. 256
Only a subset of Met-activated pathways are required to sustain oncogene addiction 252
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits 227
YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC 219
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. 203
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies 192
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts 188
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. 186
Istologia Medica 172
The tetraspanin CD151 is required for met-dependent signaling and tumor cell growth 158
Activation of RAS family members confers resistance to ROS1 targeting drugs. 146
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. 145
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort 123
Targeted therapies in cancer and mechanisms of resistance. 122
MicroRNAs impair MET-mediated invasive growth 119
Targeted therapies for gastric cancer: failures and hopes from clinical trials 117
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 98
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 93
The Semaphorin 4D receptor controls invasive growth by coupling with Met 89
Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility 88
A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer 87
Autocrine signaling of NRP1 ligand galectin-1 elicits resistance to BRAF-targeted therapy in melanoma cells 81
The landscape of d16HER2 splice variant expression across HER2-positive cancers 77
Semaphorin 4D regulates gonadotropin hormone-releasing Hormone-1 neuronal migration through Plexin B1-Met Complex 76
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 76
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers 73
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages 72
Silencing the MET oncogene leads to regression of experimental tumors and metastases 71
HGF/MET signaling protects Plasmodium infected host cells from apoptosis 70
MET overexpression turns human primary osteoblasts into osteosarcomas 66
Sema4D induces angiogenesis through Met recruitment by Plexin B1 63
Hepatocyte growth factor and its receptor are required for malaria infection 62
Hepatocyte growth factor/met system 62
p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling 62
Microsatellite instability in Gastric Cancer: Between lights and shadows 62
Interplay between scatter factor receptors and B plexins controls invasive growth 61
Molecularly targeted therapies for gastric cancer. State of the art 61
Cancer therapy: can the challenge be MET? 60
Patient-derived cancer models 58
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling 57
HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial 56
EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. 56
The importance of being CAFs (in cancer resistance to targeted therapies) 55
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. 50
Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS) 48
Oncogenes and tumor suppressor genes 43
null 36
Patient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review 31
null 21
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models 21
Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape 15
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer 13
Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations 10
Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair 8
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 7
Totale 6.513
Categoria #
all - tutte 18.408
article - articoli 0
book - libri 0
conference - conferenze 325
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.733


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020609 0 0 0 0 0 196 104 74 90 55 56 34
2020/2021666 39 46 47 76 38 32 90 40 58 58 42 100
2021/20221.096 74 81 86 78 58 45 63 58 48 82 256 167
2022/20231.111 103 97 37 86 131 240 75 63 118 25 76 60
2023/2024632 80 102 31 42 47 64 29 41 21 40 64 71
2024/2025813 25 125 68 158 333 104 0 0 0 0 0 0
Totale 6.513